Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti–IFN-γ Immunodeficiency - Takeaways - MDSpire

Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti–IFN-γ Immunodeficiency

  • By

  • Valerie Chiang

  • Freya Kit Lam Chung

  • Nga Yi Leung

  • Wai Ki Ip

  • Gordon Kwok Ho Chu

  • James Kwong Yew Hooi

  • Jane Chi Yan Wong

  • Elaine Yuen Ling Au

  • Philip Hei Li

  • July 15, 2026

Share

  • 1

    Autoantibodies against cytokines can lead to acquired immunodeficiency syndromes, often resembling primary immunodeficiencies.

  • 2

    AIGA immunodeficiency is characterized by anti-interferon-γ autoantibodies, resulting in increased susceptibility to opportunistic infections.

  • 3

    Diagnosis of AIGA immunodeficiency involves detecting autoantibodies and confirming their pathogenicity through Stat1 phosphorylation inhibition.

  • 4

    The AIGA-PROTECT registry aims to define the natural history and treatment response in patients with AIGA immunodeficiency.

  • 5

    Rituximab is used off-label for AIGA immunodeficiency in Hong Kong, with treatment decisions based on clinical severity and infection burden.

Original Source(s)

Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti–IFN-γ Immunodeficiency

  • by Valerie Chiang, Freya Kit Lam Chung, Nga Yi Leung, Wai Ki Ip, Gordon Kwok Ho Chu, James Kwong Yew Hooi, Jane Chi Yan Wong, Elaine Yuen Ling Au, Philip Hei Li

  • July 15, 2026

Related Content

Risk prediction models for postherpetic neuralgia: a systematic review and meta-analysis

Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections

30-day outcomes for self-gripping mesh versus non-self-gripping mesh in minimally invasive extraperitoneal ventral hernia repair